A pharmacoeconomic appraisal of therapies for hepatitis B and C

K. M. Shermock; M. E. Temple; Z. M. Younossi

doi:10.1517/14656566.2.2.205

A pharmacoeconomic appraisal of therapies for hepatitis B and C

K. M. Shermock, M. E. Temple, Z. M. Younossi

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

In the recent years, advances in the treatment of chronic hepatitis B and C have shown that newer, more expensive therapy may result in higher sustained viral response rates. In light of this, the pertinent question for healthcare decision-makers centres around whether this increase in efficacy 'justifies' the additional cost. Pharmacoeconomics is dedicated to helping answer these types of questions. In this article, we will discuss the clinical aspects of hepatitis B and C, recent advances in treatment and studies of the cost-effectiveness of these treatments.

Original language	English (US)
Pages (from-to)	205-211
Number of pages	7
Journal	Expert opinion on pharmacotherapy
Volume	2
Issue number	2
DOIs	https://doi.org/10.1517/14656566.2.2.205
State	Published - 2001
Externally published	Yes

Keywords

Cost-effectiveness
Hepatitis B
Hepatitis C
Interferon

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1517/14656566.2.2.205

Cite this

@article{6b7fbdbb66cd4353881c9357e798f1e4,

title = "A pharmacoeconomic appraisal of therapies for hepatitis B and C",

abstract = "In the recent years, advances in the treatment of chronic hepatitis B and C have shown that newer, more expensive therapy may result in higher sustained viral response rates. In light of this, the pertinent question for healthcare decision-makers centres around whether this increase in efficacy 'justifies' the additional cost. Pharmacoeconomics is dedicated to helping answer these types of questions. In this article, we will discuss the clinical aspects of hepatitis B and C, recent advances in treatment and studies of the cost-effectiveness of these treatments.",

keywords = "Cost-effectiveness, Hepatitis B, Hepatitis C, Interferon",

author = "Shermock, {K. M.} and Temple, {M. E.} and Younossi, {Z. M.}",

year = "2001",

doi = "10.1517/14656566.2.2.205",

language = "English (US)",

volume = "2",

pages = "205--211",

journal = "Expert opinion on pharmacotherapy",

issn = "1465-6566",

publisher = "Informa Healthcare",

number = "2",

}

TY - JOUR

T1 - A pharmacoeconomic appraisal of therapies for hepatitis B and C

AU - Shermock, K. M.

AU - Temple, M. E.

AU - Younossi, Z. M.

PY - 2001

Y1 - 2001

N2 - In the recent years, advances in the treatment of chronic hepatitis B and C have shown that newer, more expensive therapy may result in higher sustained viral response rates. In light of this, the pertinent question for healthcare decision-makers centres around whether this increase in efficacy 'justifies' the additional cost. Pharmacoeconomics is dedicated to helping answer these types of questions. In this article, we will discuss the clinical aspects of hepatitis B and C, recent advances in treatment and studies of the cost-effectiveness of these treatments.

AB - In the recent years, advances in the treatment of chronic hepatitis B and C have shown that newer, more expensive therapy may result in higher sustained viral response rates. In light of this, the pertinent question for healthcare decision-makers centres around whether this increase in efficacy 'justifies' the additional cost. Pharmacoeconomics is dedicated to helping answer these types of questions. In this article, we will discuss the clinical aspects of hepatitis B and C, recent advances in treatment and studies of the cost-effectiveness of these treatments.

KW - Cost-effectiveness

KW - Hepatitis B

KW - Hepatitis C

KW - Interferon

UR - http://www.scopus.com/inward/record.url?scp=0035001994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035001994&partnerID=8YFLogxK

U2 - 10.1517/14656566.2.2.205

DO - 10.1517/14656566.2.2.205

M3 - Review article

C2 - 11336580

AN - SCOPUS:0035001994

SN - 1465-6566

VL - 2

SP - 205

EP - 211

JO - Expert opinion on pharmacotherapy

JF - Expert opinion on pharmacotherapy

IS - 2

ER -

A pharmacoeconomic appraisal of therapies for hepatitis B and C

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this